Navigation Links
GlucoWatch G2™ Biographer

ProductsGlucoWatch G2™ Biographer
Company Animas Corporation
Item GlucoWatch G2™ Biographer
Features 
  • Provides automatic noninvasive readings as frequently as every 10 minutes for up to 13 hours
  • Identifies almost 6 times more hypoglycemic events than twice daily finger-stick blood glucose testing
  • Detects 13 times more hyperglycemic events than twice daily finger-stick blood glucose testing
  • Can alert patients to potentially dangerous glucose changes
  • 95% of GlucoWatch G2TM Biographer readings are clinically accurate or acceptable
  • Facilitates both acute and long-term therapy adjustments
Description The GlucoWatch G2 Biographer is intended for detecting trends and tracking patterns in glucose levels in adults (aged 18 and older) and children/adolescents (aged 7 to 17) with diabetes. Parents should supervise the use of the G2 Biographer with their children/adolescents. The G2 Biographer is intended to supplement, not replace, conventional blood glucose monitoring. Interpretation of G2 Biographer results should be based on the trends and patterns seen with several sequential readings over time. The G2 Biographer may not be appropriate for use every day or with every patient. Assessing patient motivation and presenting patients with a realistic picture of G2 Biographer benefits and limitations are essential for successful use.
Info Animas Corporation
Customer Service: 877.767.7373
Web site: http://www.animascorp.com

Related medicine products :

1. Novus 2000 argon laser
2. Novus Valve Systems
3. CapSureFix Novus Lead Tip
4. CapSure SP Novus
5. CapSureZ Novus
6. CapSure Novus
7. CapSureFix Novus
8. CapSureSP Novus
9. Novus Varia
10. Novus Verdi
11. Novus Spectra Photocoagulator
Breaking Medicine Technology:Boston Scientific Announces Pricing of $2 Billion of Senior Notes 2Boston Scientific Announces Pricing of $2 Billion of Senior Notes 3Phase III CONFIRM Study Shows FASLODEX(R) (fulvestrant) Injection 500 mg May Delay Time of Disease Progression Over 250-mg Dose in Postmenopausal Women With Hormone Receptor-Positive Advanced Breast Cancer 2Phase III CONFIRM Study Shows FASLODEX(R) (fulvestrant) Injection 500 mg May Delay Time of Disease Progression Over 250-mg Dose in Postmenopausal Women With Hormone Receptor-Positive Advanced Breast Cancer 3Phase III CONFIRM Study Shows FASLODEX(R) (fulvestrant) Injection 500 mg May Delay Time of Disease Progression Over 250-mg Dose in Postmenopausal Women With Hormone Receptor-Positive Advanced Breast Cancer 4Phase III CONFIRM Study Shows FASLODEX(R) (fulvestrant) Injection 500 mg May Delay Time of Disease Progression Over 250-mg Dose in Postmenopausal Women With Hormone Receptor-Positive Advanced Breast Cancer 5Phase III CONFIRM Study Shows FASLODEX(R) (fulvestrant) Injection 500 mg May Delay Time of Disease Progression Over 250-mg Dose in Postmenopausal Women With Hormone Receptor-Positive Advanced Breast Cancer 6AdEx Media, Inc. Signs Agreement with Medical Alarm Concepts 2AdEx Media, Inc. Signs Agreement with Medical Alarm Concepts 3Delayed First Visit to Dentist Can Affect Childrens Lifelong Oral Health 58581 1Delayed First Visit to Dentist Can Affect Childrens Lifelong Oral Health 58581 2Sleep Center at Baylor Dallas One of Select Centers in North Texas to Receive Accreditation 58576 1Sleep Center at Baylor Dallas One of Select Centers in North Texas to Receive Accreditation 58576 2United States Patent Office Allows Claims Covering the Approved Administration of Kuvan with Food 5114 1United States Patent Office Allows Claims Covering the Approved Administration of Kuvan with Food 5114 2United States Patent Office Allows Claims Covering the Approved Administration of Kuvan with Food 5114 3